Sign In
Buy POAI
$4.91
+0 (+0%)
At Close: Jun 22, 2026
Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
04:52am, Tuesday, 21'st Apr 2026
Predictive Oncology Inc. (NASDAQ: POAI - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.45 and traded as
Predictive Oncology Q4 Earnings Call Highlights
01:07am, Friday, 03'rd Apr 2026
Axe Compute (NASDAQ: AGPU) used its fiscal year 2025 investor presentation to outline its transition toward a GPU compute capacity platform, discuss early commercial traction following its rebrand, an
Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened
04:13am, Thursday, 19'th Mar 2026
Predictive Oncology Inc. (NASDAQ: POAI - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of
Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison
01:15am, Tuesday, 10'th Feb 2026
Predictive Oncology (NASDAQ: POAI - Get Free Report) and Mitesco (OTCMKTS:MITI - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two busin
Financial Analysis: Predictive Oncology (NASDAQ:POAI) and Healthcare Triangle (NASDAQ:HCTI)
01:08am, Friday, 30'th Jan 2026
Healthcare Triangle (NASDAQ: HCTI - Get Free Report) and Predictive Oncology (NASDAQ: POAI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the
Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened
03:52am, Saturday, 10'th Jan 2026
Predictive Oncology Inc. (NASDAQ: POAI - Get Free Report) shares passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $10.47 and traded as low as
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
08:00am, Friday, 12'th Dec 2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU) (the “Company” or “Axe Compute”) today announced that it has changed its name to Axe Compute Inc., with its common s
Predictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks Transcript
12:07pm, Monday, 17'th Nov 2025
Predictive Oncology Inc. ( POAI ) Q3 2025 Earnings Call November 17, 2025 9:00 AM EST Company Participants Raymond Vennare - CEO & Chairman Joshua Blacher - Interim Chief Financial Officer Thomas McLa
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
05:12pm, Friday, 14'th Nov 2025
PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
08:00am, Tuesday, 14'th Oct 2025
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy
09:00am, Wednesday, 08'th Oct 2025
Investment creates the world's first Strategic Compute Reserve Strategy complements Predictive Oncology's AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWS
Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements
Predictive Oncology Announces 1-for-15 Reverse Stock Split
08:00am, Thursday, 25'th Sep 2025
Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025 Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
09:00am, Thursday, 04'th Sep 2025
Collaboration builds upon positive results utilizing Predictive Oncology's AI platform to identify new indications for existing drugs Collaboration builds upon positive results utilizing Predictive On
NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sal
